Head & Neck trials now recruiting
TROG 14.03 (EORTC 1219) - the aim of this study is to determine whether the addition of nimorazole to the standard treatment (radiotherapy in combination with chemotherapy using cisplatin) shows activity against Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers and is safe.
Primary sponsor: European Organisation for Research and Treatment of Cancer (EORTC)
Collaborating group: TROG; Danish Head and Neck Cancer Group (DAHANCA)
TROG 12.01 (HPV) - this study aims to compare radiotherapy combined with either cetuximab or cisplatin in patients with locoregionally advanced HPV positive oropharyngeal squamous cell carcinoma (OPSCC) (located at the base of tongue or tonsil).
Primary sponsor: TROG